Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin Pharmaceutical is ...

BioMarin’s first quarter saw revenue growth driven by continued demand for its enzyme therapies and Voxzogo, but the company ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best healthcare stocks to buy for the long term. Evercore ISI lifted ...

Higher manufacturing costs and a $4.8 billion acquisition weighed on first-quarter earnings, but demand grew for several treatments for rare genetic disorders fueled revenue growth.

Futures are trading lower as we get set to start the new trading week, as reports indicate that President Trump declined Iran ...

With the acquisition, BioMarin adds Galafold for Fabry disease and Pombiliti+Opfolda for Pompe disease.

BioMarin Pharmaceutical BMRN reported first-quarter 2026 adjusted earnings per share of 76 cents, missing the Zacks Consensus ...

Jean-Jacques Bienaimé, who over the course of nearly two decades grew BioMarin Pharmaceutical’s portfolio from a single commercialized asset to multiple marketed products—including a landmark approval ...

BioMarin Pharmaceutical (NASDAQ:BMRN) executives emphasized an expanded commercial portfolio and an updated 2026 growth ...

The pharmaceutical company says it could be years before it resumes efforts to redevelop 999 Third St. with buildings for offices and labs.

The last time I wrote about BioMarin Pharmaceutical (BMRN) it was with a Seeking Alpha article entitled "BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401." With respect to this ...

BioMarin disclosed late Wednesday that longtime CEO JeanJacques (JJ) Bienaimé is retiring effective December 1 and will be succeeded by Alexander Hardy, who is currently the CEO of Genentech at Roche.